BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1
(Adnkronos) – SHANGHAI, May 24, 2023 /PRNewswire/ — BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the Investigational New Drug (IND) application for the clinical trial of its proprietary BRY812,
